三元生物(301206) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 was CNY 106,086,181.83, a decrease of 79.54% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 31,976,384.64, down 83.83% year-on-year[4] - Basic earnings per share for Q3 2022 was CNY 0.16, a decline of 91.84% compared to the previous year[4] - Operating income for the first nine months of 2022 was CNY 563,363,651.68, down 56.84% year-on-year due to increased market competition[10] - The company's total revenue for the current period was CNY 563,363,651.68, a decrease of approximately 56.7% compared to CNY 1,305,360,240.59 in the same period last year[27] - The net profit for Q3 2022 was CNY 151,155,941.78, a decrease of 65.7% compared to CNY 440,682,536.29 in Q3 2021[28] - Operating profit for the quarter was CNY 169,888,387.28, a decline of 66.7% from CNY 510,138,452.87 in the same period last year[28] Assets and Liabilities - Total assets at the end of Q3 2022 reached CNY 4,798,187,821.59, an increase of 193.62% from the end of the previous year[4] - As of September 30, 2022, the total assets of Shandong Sanyuan Biotechnology Co., Ltd. amounted to CNY 4,798,187,821.59, a significant increase from CNY 1,634,157,434.85 at the beginning of the year[23] - The total liabilities of the company as of September 30, 2022, were CNY 189,942,474.74, down from CNY 588,828,870.18, a reduction of approximately 67.8%[25] Equity and Shareholder Information - The company reported a significant increase in total equity attributable to shareholders, which reached CNY 4,608,245,346.85, up 340.84% from the previous year[4] - The equity attributable to the owners of the parent company increased to CNY 4,608,245,346.85 from CNY 1,045,328,564.67, reflecting a growth of about 340.5%[25] - The total number of ordinary shareholders at the end of the reporting period was 21,514, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Nie Zaijian, holds 45.94% of the shares, totaling 92,946,000 shares[14] - The company completed a capital increase from capital reserves, increasing the total share capital from 134,883,800 shares to 202,325,700 shares, with a distribution of 5 shares for every 10 shares held[19] Cash Flow - Cash flow from operating activities for the first nine months of 2022 was CNY 90,426,851.62, down 82.62% compared to the previous year[4] - The net cash flow from operating activities for the first nine months of 2022 was ¥90,426,851.62, a decrease of 82.62% compared to the same period last year, primarily due to intensified market competition and a decline in sales prices and volumes[12] - The net cash flow from investing activities for the first nine months of 2022 was -¥3,282,248,061.08, an increase of 892.61% year-on-year, mainly due to the purchase of large bank deposits during the reporting period[12] - The net cash flow from financing activities for the first nine months of 2022 was ¥3,417,536,634.32, an increase of 53,306.88% compared to the same period last year, primarily due to funds raised from a public offering[12] Research and Development - Research and development expenses for the first nine months of 2022 amounted to CNY 31,870,190.36, a decrease of 34.44% compared to the previous year[10] - Research and development expenses amounted to CNY 31,870,190.36, down 34.5% from CNY 48,614,684.08 in the previous year[28] Operational Changes - The company obtained AEO Advanced Certification on September 30, 2022, which enhances its credibility and operational efficiency in international trade[21] - The company has changed its external auditor to Dahua Certified Public Accountants for the 2022 fiscal year, indicating a strategic shift in its auditing approach[20] - The company has not disclosed any related party relationships among the top ten shareholders[15] - The company has not reported any new product developments or market expansion strategies during the reporting period[18] Inventory and Receivables - Accounts receivable decreased significantly to CNY 33,583,700.39 from CNY 141,359,628.59, indicating a reduction of approximately 76.3%[23] - Inventory levels decreased to CNY 73,203,380.23 from CNY 112,157,402.58, representing a decline of about 34.7%[24] Cash and Cash Equivalents - The company's cash and cash equivalents as of September 30, 2022, were CNY 514,413,874.36, slightly down from CNY 515,719,690.44 at the beginning of the year[23] - The company reported a total cash and cash equivalents balance of CNY 514,832,741.03 at the end of the quarter, compared to CNY 254,249,794.17 at the end of Q3 2021[31]